316 related articles for article (PubMed ID: 30844294)
1. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
Wang K; Baldwin GS; Nikfarjam M; He H
Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G632-G640. PubMed ID: 30844294
[TBL] [Abstract][Full Text] [Related]
2. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.
Yeo D; Huynh N; Beutler JA; Christophi C; Shulkes A; Baldwin GS; Nikfarjam M; He H
Cancer Lett; 2014 May; 346(2):264-72. PubMed ID: 24491405
[TBL] [Abstract][Full Text] [Related]
3. FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.
Yeo D; He H; Patel O; Lowy AM; Baldwin GS; Nikfarjam M
BMC Cancer; 2016 Jan; 16():24. PubMed ID: 26774265
[TBL] [Abstract][Full Text] [Related]
4. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
Wang K; Huynh N; Wang X; Baldwin G; Nikfarjam M; He H
Int J Oncol; 2018 Jan; 52(1):261-269. PubMed ID: 29115428
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of retinoic acid sensitivity in pancreatic cancer.
Gupta S; Pramanik D; Mukherjee R; Campbell NR; Elumalai S; de Wilde RF; Hong SM; Goggins MG; De Jesus-Acosta A; Laheru D; Maitra A
Clin Cancer Res; 2012 Jan; 18(1):280-9. PubMed ID: 22010213
[TBL] [Abstract][Full Text] [Related]
7. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
[TBL] [Abstract][Full Text] [Related]
8. All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase.
Kuroda H; Tachikawa M; Uchida Y; Inoue K; Ohtsuka H; Ohtsuki S; Unno M; Terasaki T
Eur J Pharm Sci; 2017 May; 103():116-121. PubMed ID: 28215943
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity.
Ma Y; Dumesny C; Dong L; Ang CS; Asadi K; Zhan Y; Nikfarjam M; He H
Cell Commun Signal; 2024 May; 22(1):287. PubMed ID: 38797819
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
11. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
[TBL] [Abstract][Full Text] [Related]
12. P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Jagadeeshan S; Subramanian A; Tentu S; Beesetti S; Singhal M; Raghavan S; Surabhi RP; Mavuluri J; Bhoopalan H; Biswal J; Pitani RS; Chidambaram S; Sundaram S; Malathi R; Jeyaraman J; Nair AS; Venkatraman G; Rayala SK
Ann Oncol; 2016 Aug; 27(8):1546-56. PubMed ID: 27117533
[TBL] [Abstract][Full Text] [Related]
13. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma.
Sugimoto T; Iwagami Y; Kobayashi S; Yamanaka C; Sasaki K; Yamada D; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
Ann Surg Oncol; 2024 Jun; 31(6):3718-3736. PubMed ID: 38502294
[TBL] [Abstract][Full Text] [Related]
14. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
15. Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
Céspedes MV; Guillén MJ; López-Casas PP; Sarno F; Gallardo A; Álamo P; Cuevas C; Hidalgo M; Galmarini CM; Allavena P; Avilés P; Mangues R
Dis Model Mech; 2016 Dec; 9(12):1461-1471. PubMed ID: 27780828
[TBL] [Abstract][Full Text] [Related]
16. ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1.
Wang K; Qiu X; Zhang Z; Xu H; Tan Y; Su R; Gao F; Zhuo J; Li W; Lian Z; He H; Xu X
Cell Commun Signal; 2023 Aug; 21(1):193. PubMed ID: 37537668
[TBL] [Abstract][Full Text] [Related]
17. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
Daylami R; Muilenburg DJ; Virudachalam S; Bold RJ
J Exp Clin Cancer Res; 2014 Dec; 33(1):102. PubMed ID: 25499121
[TBL] [Abstract][Full Text] [Related]
18. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.
Froeling FE; Feig C; Chelala C; Dobson R; Mein CE; Tuveson DA; Clevers H; Hart IR; Kocher HM
Gastroenterology; 2011 Oct; 141(4):1486-97, 1497.e1-14. PubMed ID: 21704588
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
Hu G; Li F; Ouyang K; Xie F; Tang X; Wang K; Han S; Jiang Z; Zhu M; Wen D; Qin X; Zhang L
Int J Oncol; 2012 Mar; 40(3):798-806. PubMed ID: 22076649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]